Experts are optimistic about a sustained rally in the Indian stock market, with the first half of the earnings season expected to be positive. Institutional investors are making selective buys in companies with attractive valuations in comparison to peers, including Max Healthcare, Piramal, and Aurobindo. The healthcare and pharmaceutical sectors are predicted to have sustainable expenses, making them a safe investment option. Aurobindo is seen as particularly attractively valued and could see a surprise earnings boost from factors such as base effect, new launches, or rupee depreciation.